Dossier assessment
Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Routine prophylaxis of bleeding episodes in patients with severe haemophilia A without factor VIII inhibitors
Presented before-after comparison unsuitable for the assessment of the added benefit; added benefit not proven
Project details
- Project no.
- A19-26
- Commission
- Commission awarded on 18.03.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Emicizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed